Loading clinical trials...
Loading clinical trials...
Data regarding hepatocellular carcinoma (HCC) recurrence after directly acting antivirals (DAAs) given for hepatitis C virus treatment are contradictory. Surprisingly, some studies reported that DAAs ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alexandria University
NCT06902246 · Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
NCT07422753 · Hepatocellular Carcinoma (HCC)
NCT07175441 · Advanced Unresectable Hepatocellular Carcinoma
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
NCT06427941 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, and more
Alexandria University, Faculty of Medicine
Alexandria
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions